SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‐Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

ABSTRACT: Abstract Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH <2.5 µg/L and IGF-1

SUBMITTER: Gadelha M 

PROVIDER: S-EPMC6552256 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature